---
title: "Psyence Biomedical FY26 net loss widens to about USD 6.89 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290473110.md"
description: "Psyence Biomedical reported a widened net loss of approximately USD 6.89 million for fiscal 2026, remaining pre-revenue. R&D expenses more than doubled to USD 1.47 million due to accelerated Phase IIb psilocybin trials. Professional fees rose to USD 3.65 million, including a USD 1.5 million settlement related to the KAOS Group dispute. Cash reserves increased to USD 7.49 million, and the company received an Australian R&D rebate of USD 292,247."
datetime: "2026-06-22T20:02:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290473110.md)
  - [en](https://longbridge.com/en/news/290473110.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290473110.md)
---

# Psyence Biomedical FY26 net loss widens to about USD 6.89 million

-   Psyence Biomedical posted a net loss of about USD 6.89 million for fiscal 2026, remaining pre-revenue with no revenue from product sales. \* R&D expense more than doubled to USD 1.47 million, reflecting accelerated activity in its Phase IIb psilocybin trial in palliative care patients. \* Professional and consulting fees climbed to USD 3.65 million, while the company recorded a USD 1.5 million net settlement expense tied to the KAOS Group dispute. \* Cash rose to USD 7.49 million, lifting working capital to USD 8.49 million; an Australian R&D cash rebate of USD 292,247 was received. \* PBM increased its PsyLabs stake to 27.93%, taking the investment to the equity method; carrying value was USD 8.06 million at March 31, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-070607), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PBM.US](https://longbridge.com/en/quote/PBM.US.md)
- [PBMWW.US](https://longbridge.com/en/quote/PBMWW.US.md)

## Related News & Research

- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Kreditbanken posts 2026 half-year report release](https://longbridge.com/en/news/296349936.md)
- [Innventure publishes shareholder letter after Q2 2026 results](https://longbridge.com/en/news/296354399.md)
- [Xylem sets quarterly distribution at R$ 0.75 per unit for 3Q 2026](https://longbridge.com/en/news/296117630.md)
- [Masoval to present Q2 2026 results in investor briefing](https://longbridge.com/en/news/296509895.md)